Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 107.6% in June

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 27,250 shares, a growth of 107.6% from the May 31st total of 13,125 shares. Currently, 1.6% of the shares of the stock are short sold. Based on an average trading volume of 24,781 shares, the short-interest ratio is currently 1.1 days.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in BOLT. Squarepoint Ops LLC increased its position in Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares during the period. Shay Capital LLC acquired a new position in shares of Bolt Biotherapeutics during the third quarter worth $85,000. Susquehanna International Group LLP bought a new stake in shares of Bolt Biotherapeutics in the third quarter worth $89,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter worth $112,000. Finally, T3 Companies LLC acquired a new stake in Bolt Biotherapeutics in the fourth quarter valued at $208,000. 86.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BOLT. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $34.67.

Bolt Biotherapeutics Price Performance

NASDAQ BOLT traded up $0.29 during trading on Tuesday, hitting $4.19. 2,122 shares of the company’s stock were exchanged, compared to its average volume of 27,182. The company has a market cap of $8.04 million, a PE ratio of -0.26 and a beta of 1.12. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.98. Bolt Biotherapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $7.20. The stock’s 50 day moving average price is $4.69 and its two-hundred day moving average price is $5.01.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. Research analysts expect that Bolt Biotherapeutics will post -11.1 EPS for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.